Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention

Archives of Internal Medicine

Volumn 159, Issue 21, 1999, Pages 2524-2528

  Bennett, Charles L ^a,b,c,g   Davidson, Charles J ^a   Raisch, Dennis W ^d   Weinberg, Peter D ^a   Bennett, Richard H ^e   Feldman, Marc D ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TICLOPIDINE;

ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CORONARY STENT; HUMAN; MORTALITY; PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

CEREBROVASCULAR ACCIDENT; CORONARY THROMBOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STENTS; TICLOPIDINE;

EID: 0033596066     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.21.2524     Document Type: Article

References (21)

1. Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1996;45:139-159.
2. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med. 1998;339:1578-1584.
3. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
4. Moake J. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol. 1997;34:83-89.
5. Bennett CL, Kiss JE, Weinberg PD, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998;352:1036-1037.
6. Ticlid (ticlopidine HCI) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1998.
7. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med. 1998;128:541-544.
8. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA. 1999;281:806-810.
9. Bennett CL, Davidson CJ, Green D, Weinberg PD, Feldman D. Thrombotic thrombocytopenic purpura following ticlopidine and coronary artery stenting. JAMA. In press.
10. Leon MB, Baim DS, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary stenting. N Engl J Med. 1998;339:1665-1671.
11. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996;93:215-222.
12. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
13. Gent M, Easton JD, Hachinski VC, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
14. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients (TASS). N Engl J Med. 1989;321:501-507.
15. Ticlid (ticlopidine HCI) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1991.
16. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA. 1998;279: 1571-1573.
17. Wysowski DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [letter]. JAMA. 1996;276:952.
18. Berger PB, Grill DE, Melby SJ, Bell MR, Holmes DR Jr. Can ticlopidine be safely discontinued two weeks after coronary stent placement? Paper presented at: Proceedings of the American College of Cardiology, March 29-April 1, 1998, Atlanta, Ga.
19. A randomized, blinded trial of clopidogrel versus aspirin in patients at high risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996;348: 1329-1339.
20. Green D. CAPRIE trial correspondence [letter]. Lancet. 1997;349:354-355.
21. Winslow R. Hematologist says Ticlid is implicated by data on cases of TTP blood disorder. Wall Street Journal. March 30, 1998:B5.